Related Experiment Video

Updated: Jul 28, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta

F Boudsocq1, P Benaim, Y Canitrot

  • 1Equipe Instabilité Génétique et Cancer, Institut de Pharmacologie et de Biologie Structurale, Unité Mixte Recherche Centre National de la Recherche Scientifique 5089, Toulouse, France.

Molecular Pharmacology
|February 11, 2005
PubMed

Insights

Researchers discovered masticadienonic acid (MA), a potent inhibitor of DNA polymerase beta (Pol beta). MA sensitizes cisplatin-resistant tumor cells, suggesting its potential use in combination cancer therapy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • DNA polymerase beta (Pol beta) is an error-prone enzyme implicated in genetic instability and cisplatin resistance in tumors.
  • Targeting Pol beta offers a potential strategy to overcome drug resistance in cancer therapy.

Purpose of the Study:

  • To identify novel inhibitors of DNA polymerase beta (Pol beta) from natural extracts.
  • To evaluate the efficacy of these inhibitors, particularly masticadienonic acid (MA), in sensitizing cisplatin-resistant cancer cells.

Main Methods:

  • High-throughput screening of 8448 semipurified natural extracts to identify Pol beta inhibitors.
  • In vitro assays to assess the specificity of inhibitors against Pol beta-mediated DNA synthesis.
  • Docking simulations to predict the binding mechanism of masticadienonic acid (MA) to Pol beta.
  • Evaluation of MA's effect on translesion synthesis (TLS) across cisplatin adducts and sensitization of resistant tumor cells.

Main Results:

  • Masticadienonic acid (MA) was identified as a potent and specific inhibitor of Pol beta, with an IC50 of 8 microM.
  • MA demonstrated a favorable binding interaction with Pol beta, substituting for single-strand DNA.
  • MA effectively inhibited Pol beta-mediated translesion synthesis (TLS) across cisplatin adducts.
  • MA sensitized cisplatin-resistant human tumor cells (2008C13*5.25) to cisplatin treatment.

Conclusions:

  • Masticadienonic acid (MA) is a highly potent inhibitor of DNA polymerase beta (Pol beta).
  • MA's ability to inhibit Pol beta and sensitize resistant cells suggests its therapeutic potential.
  • MA, in combination with cisplatin, may enhance anticancer treatment efficacy.

More Related Videos

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...